The VHP Market Is Heading to $3.4 Billion. Here Is What That Means for Manufacturers Who Haven't Yet Decided.

Market forecasts are often used as marketing instruments. A research firm publishes a growth projection, a supplier quotes it in a press release, and the number circulates as evidence of momentum rather than as data for decision-making. This article is not that exercise.

The Toward Healthcare forecast published in April 2026 projects the vaporized hydrogen peroxide sterilizer market at $1.45 billion in 2025, growing to $3.4 billion by 2035 at an 8.9% compound annual growth rate. That projection deserves examination — not as validation of VHP's momentum, but as a data point that reflects underlying structural forces worth understanding. The market does not grow by 8.9% annually because research analysts say it should. It grows because specific industry dynamics are converting manufacturers who had previously chosen other methods, or deferred the decision entirely, into VHP adopters.

Understanding what is actually driving that conversion is more useful to a manufacturer making a capital decision than the headline CAGR alone.

The Composition of the Market

The VHP sterilizer market is not a monolithic category. It encompasses hospital-grade room decontamination systems, pharmaceutical isolator decontamination systems, medical device sterilization chambers, and laboratory biosafety decontamination equipment. Each segment has a different adoption driver, a different customer base, and a different growth trajectory.

According to market analysis from Grand View Research, medical device sterilization is the largest application segment by revenue — accounting for approximately 42% of the total market in 2025. This reflects the accumulated impact of FDA's January 2024 Category A reclassification and ISO 22441:2022 consensus standard recognition, which together resolved the regulatory pathway uncertainty that had historically limited VHP adoption in device sterilization relative to the installed base of EtO and irradiation.

Pharmaceutical applications — isolator decontamination, RABS decontamination, and aseptic fill-finish environment management — represent the second-largest segment, growing faster than device sterilization in absolute percentage terms because the Annex 1 (2022 revision) mandate for sporicidal validation in isolators has created a defined compliance driver that did not exist at comparable force before 2022.

Healthcare facility decontamination — whole-room decontamination for infection control, particularly for C. difficile, MRSA, and other spore-forming healthcare-associated pathogens — is a distinct market segment with its own dynamics. This is not the segment where PuroGen operates, but its inclusion in market projections inflates the total addressable market figure relative to what is directly relevant to device manufacturers.

North America leads global market share, at approximately 38% of the 2025 total. This reflects the density of medical device manufacturing infrastructure, the FDA regulatory framework that incentivizes domestic sterilization capability, and the concentration of pharmaceutical fill-finish operations in the U.S. and Canada. Europe is the second-largest region, driven by EU MDR compliance timelines and Annex 1 implementation.

What the Growth Rate Actually Reflects

An 8.9% CAGR over a decade is meaningfully above typical medical device capital equipment growth rates — which historically run in the 4–6% range for established equipment categories. The premium is driven by three structural factors that are not cyclical.

**EtO regulatory attrition.** The EPA's emissions reduction program, regardless of the pace of implementation changes at any given moment, has raised the operational cost profile of EtO sterilization. Capital investments in abatement infrastructure at commercial EtO facilities are already reflected in pricing; those investments are not reversible. Manufacturing facilities that use EtO in-house face ongoing occupational exposure monitoring requirements, community relations exposure, and insurance cost considerations that did not exist at the same intensity before 2024. Each manufacturer that exits EtO for operational cost or risk reasons represents a customer conversion that is structurally unlikely to reverse.

**Irradiation supply constraints.** The global cobalt-60 supply chain — which supports gamma irradiation sterilization, the dominant modality for the high-volume device market — has been under capacity pressure since the reactor life cycle transitions at the primary North American Co-60 sources. The consequence is that new gamma sterilization capacity is not being built at a rate that matches the projected demand from device manufacturers. Manufacturers who cannot obtain reliable gamma sterilization contracts — or who find that contract terms have become less favorable due to capacity tightness — are evaluating in-house VHP as an alternative to a constrained external supply chain.

**Annex 1 and pharma isolator compliance.** The EU Annex 1 (2022 revision) mandates validated decontamination programs for aseptic manufacturing environments with a specificity that did not exist in the pre-2022 Annex 1. Section 4.22 requires that sporicidal agents used in isolators and RABS be validated — a requirement that is driving systematic re-qualification of existing isolator decontamination programs and new validation investment at facilities that had previously operated on less-documented practices. This creates a defined compliance investment that the VHP market is capturing: each Annex 1-driven isolator validation program represents a market event.

The Inventor's Position in a Growing Category

There is a way to present market growth data that positions the company presenting it as a beneficiary of favorable tailwinds. That framing is not accurate for PuroGen, and it is not how this market data should be interpreted.

PuroGen did not position itself in VHP because of a 2025 market forecast. The company's patent portfolio, validation heritage, and engineering architecture were developed over decades — through the period when VHP was a Category B method with uncertain regulatory standing, before ISO 22441 existed, and before any analyst was projecting $3.4 billion market growth. The technology came first. The market is a downstream consequence of the validation work that was done when the commercial case was less obvious.

What the market forecast does is validate the structural premises on which PuroGen has operated: that VHP is the superior sterilization modality for temperature-sensitive and biologically complex materials; that in-house sterilization capability is superior to external contract dependency; and that the regulatory framework would eventually converge on the method's actual efficacy profile. The forecast confirms that those premises are now broadly shared, not that they are newly discovered.

For manufacturers who have not yet made a sterilization technology decision — or who have been operating on legacy EtO or irradiation programs while deferring the evaluation — the market growth projection is a lagging indicator, not a leading one. The regulatory and operational conditions that are driving market growth are already in effect. The manufacturers currently entering the market are not the first movers who helped establish the framework; they are the second wave, operating with the benefit of that framework and its accumulated precedent.

The Decision Framework: What the Growth Forecast Doesn't Tell You

A market growing at 8.9% annually does not tell a specific manufacturer whether VHP is the right choice for their specific products, their specific regulatory environment, or their specific operational configuration. The aggregate market trajectory is not a substitute for that analysis.

The relevant questions for a manufacturer evaluating VHP are narrower and more concrete:

What is the temperature sensitivity profile of my product, and does it tolerate EtO processing or irradiation dose without material or biological degradation? For temperature-sensitive devices, combination products with biologic components, and allograft tissue, the answer is often no — and VHP's 30–50°C process temperature is not a preference, it is a requirement.

What is the current cost structure of my sterilization dependency, and how has it changed in the last 24 months? For manufacturers with EtO contracts, the pricing environment has changed materially. For manufacturers with irradiation contracts, capacity availability has changed. The market growth forecast does not describe those specific changes, but they are the actual inputs to the capital decision.

What is the regulatory pathway for my specific device and markets? FDA's Category A recognition and ISO 22441:2022 have resolved the primary regulatory objection that historically limited VHP adoption in U.S. submissions. EU MDR, Health Canada, TGA, and PMDA all operate within ISO-harmonized frameworks that accept ISO 22441. The regulatory pathway has not been simplified — validation rigor is unchanged — but its predictability and multi-market portability have improved substantially.

What is the strategic value of owning the sterilization step rather than outsourcing it? For manufacturers with complex products, tight release timelines, or supply chain risk exposure that crystallized during 2020–2023, in-house sterilization capability is a supply chain resilience investment as much as it is a cost optimization.

A $3.4 Billion Market by 2035 — and What Preceded It

The $3.4 billion projection, if realized, will represent a sterilization category that has more than doubled from its 2025 level in a decade. Behind that projection is the cumulative adoption work done by the manufacturers who validated VHP processes, submitted to FDA under ISO 22441, qualified isolator decontamination programs under Annex 1, and demonstrated in-house sterilization ROI before the market forecast confirmed the trend.

PuroGen's position in that history is not as a market participant responding to forecast conditions. It is as an inventor whose platforms — [SteriFlex](/steriflex) for programmable parametric sterilization, and the underlying science documented in the [validation heritage](/science) that spans decades of process development — preceded the market conditions that are now generating that forecast. The platforms were designed for what the market is now demanding: independent parametric control, validated performance at SAL 10⁻⁶, compatibility with temperature-sensitive and biologically complex materials, and an architecture adaptable to device manufacturers, pharmaceutical manufacturers, and research environments.

For manufacturers evaluating where VHP fits in their long-term sterilization strategy, the relevant question is not whether the market will grow. It will. The question is whether the operational and regulatory conditions that are driving that growth apply to their specific situation — and at what point the cost of deferral exceeds the cost of decision. The [solutions page](/solutions) and [strategic collaboration pathways](/strategic) at PuroGen are the appropriate contexts for that conversation.

Frequently Asked Questions

**Where does the $1.45 billion / $3.4 billion market figure come from?**

The figures are from the Toward Healthcare VHP Sterilizers Market report (April 2026), which projects the global VHP sterilizer market at $1.45 billion in 2025 growing to $3.4 billion by 2035 at an 8.9% CAGR. This is consistent with the directional projections published by Grand View Research, Verified Market Research, and other market research firms covering the sterilization equipment category. Market research projections should be interpreted as structural trend signals, not precise forecasts — the underlying drivers (EtO regulatory pressure, irradiation supply constraints, Annex 1 compliance requirements) are well-documented, even if the specific revenue projections carry inherent uncertainty.

**What is driving the 8.9% CAGR, specifically?**

The three primary structural drivers are: (1) EtO sterilization attrition, as operational costs, regulatory compliance burden, and occupational exposure liability have made EtO less economically and operationally attractive for a growing segment of manufacturers; (2) cobalt-60 supply constraints, which are limiting the availability and commercial terms for gamma irradiation sterilization; and (3) Annex 1 (2022 revision) compliance requirements, which have created a defined compliance investment in isolator decontamination programs at pharmaceutical manufacturers across the EU and globally. Each driver converts a portion of the existing sterilization install base from EtO, gamma, or unvalidated alternatives into the VHP market.

**Is the medical device segment or the pharma segment growing faster?**

Pharmaceutical applications — isolator decontamination and aseptic fill-finish environment management — are growing faster in percentage terms because Annex 1 compliance is creating a near-term, defined investment driver. Medical device sterilization is the larger absolute segment (approximately 42% of total market by revenue in 2025) and will remain so, because device sterilization represents the larger installed base that is transitioning from EtO and irradiation. Both segments are growing above the historical equipment category baseline.

**Does market growth change PuroGen's commercial strategy?**

No. PuroGen's platforms and commercial pathways — direct deployment, private label and OEM manufacturing, and strategic collaboration — were developed based on the technology's capabilities and validation heritage, not based on market forecast conditions. What the market forecast reflects is that the structural environment is increasingly aligned with the value proposition PuroGen has operated on for decades. That alignment is not a change in direction; it is the long-run outcome of having built the technology before the market conditions made it obvious.

**What is the regulatory landscape for VHP in the largest global markets?**

In the United States, FDA's Category A designation (January 2024) and ISO 22441:2022 consensus standard recognition provide the established regulatory pathway for VHP sterilization in device submissions. In the European Union, Notified Bodies are actively accepting ISO 22441-aligned technical documentation in CE-marking reviews under EU MDR 2017/745. Health Canada, TGA (Australia), and PMDA (Japan) all operate within ISO-harmonized frameworks that accept ISO 22441 as the applicable validation standard for VHP. For a detailed treatment of the global regulatory landscape, see the [ISO 22441 international regulatory acceptance article](/insights/iso-22441-international-regulatory-acceptance).

**What should a manufacturer do with this market information?**

Use it as context, not as a decision driver. The relevant decision inputs are product-specific: temperature sensitivity, current sterilization contract economics, regulatory submission pathway for target markets, and supply chain resilience objectives. The market forecast confirms that the structural conditions driving VHP adoption are broadly present — it does not specify whether those conditions apply to a particular manufacturer's situation. The [PuroGen solutions page](/solutions) and [contact](/contact) are the appropriate starting points for a manufacturer-specific evaluation.